Table 1 Baseline characteristics of liver cancer patients (analysis of variance)
From: PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma
Characteristics | Low expression of PDCL3 | High expression of PDCL3 | p |
|---|---|---|---|
T stage, n (%) | 0.009 | ||
 T1 | 107 (28.8%) | 76 (20.5%) |  |
 T2 | 38 (10.2%) | 57 (15.4%) |  |
 T3 | 34 (9.2%) | 46 (12.4%) |  |
 T4 | 5 (1.3%) | 8 (2.2%) |  |
N stage, n (%) | 0.622 | ||
 N0 | 125 (48.4%) | 129 (50%) |  |
 N1 | 1 (0.4%) | 3 (1.2%) |  |
M stage, n (%) | 0.624 | ||
 M0 | 129 (47.4%) | 139 (51.1%) |  |
 M1 | 1 (0.4%) | 3 (1.1%) |  |
Pathologic stage, n (%) | 0.017 | ||
 Stage I | 101 (28.9%) | 72 (20.6%) |  |
 Stage II | 37 (10.6%) | 50 (14.3%) |  |
 Stage III | 35 (10%) | 50 (14.3%) |  |
 Stage IV | 2 (0.6%) | 3 (0.9%) |  |
Histologic grade, n (%) | < 0.001 | ||
 G1 | 33 (8.9%) | 22 (6%) |  |
 G2 | 105 (28.5%) | 73 (19.8%) |  |
 G3 | 43 (11.7%) | 81 (22%) |  |
 G4 | 3 (0.8%) | 9 (2.4%) |  |
Age, median (IQR) | 64 (53.5, 70) | 59 (50.25, 67.75) | 0.011 |